Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages.
Aged, 80 and over
Aging
/ blood
Biomarkers
/ blood
Cardiovascular Diseases
/ blood
Female
Humans
Longevity
/ physiology
Longitudinal Studies
Male
Multivariate Analysis
Natriuretic Peptide, Brain
/ blood
Peptide Fragments
/ blood
Predictive Value of Tests
Prospective Studies
Risk Factors
Serum Albumin
/ analysis
Surveys and Questionnaires
/ statistics & numerical data
Survival Analysis
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
30 07 2020
30 07 2020
Historique:
received:
27
10
2018
accepted:
07
07
2020
entrez:
1
8
2020
pubmed:
1
8
2020
medline:
9
9
2020
Statut:
epublish
Résumé
Supercentenarians (those aged ≥110 years) are approaching the current human longevity limit by preventing or surviving major illness. Identifying specific biomarkers conducive to exceptional survival might provide insights into counter-regulatory mechanisms against aging-related disease. Here, we report associations between cardiovascular disease-related biomarkers and survival to the highest ages using a unique dataset of 1,427 oldest individuals from three longitudinal cohort studies, including 36 supercentenarians, 572 semi-supercentenarians (105-109 years), 288 centenarians (100-104 years), and 531 very old people (85-99 years). During follow-up, 1,000 participants (70.1%) died. Overall, N-terminal pro-B-type natriuretic peptide (NT-proBNP), interleukin-6, cystatin C and cholinesterase are associated with all-cause mortality independent of traditional cardiovascular risk factors and plasma albumin. Of these, low NT-proBNP levels are statistically associated with a survival advantage to supercentenarian age. Only low albumin is associated with high mortality across age groups. These findings expand our knowledge on the biology of human longevity.
Identifiants
pubmed: 32732919
doi: 10.1038/s41467-020-17636-0
pii: 10.1038/s41467-020-17636-0
pmc: PMC7393489
doi:
Substances chimiques
Biomarkers
0
Peptide Fragments
0
Serum Albumin
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3820Références
Lakatta, E. G. & Levy, D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease. Circulation 107, 139–146 (2003).
pubmed: 12515756
Kennedy, B. K. et al. Geroscience: linking aging to chronic disease. Cell 159, 709–713 (2014).
pubmed: 4852871
pmcid: 4852871
Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095–2128 (2012).
pubmed: 23245604
Roth, G. A. et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N. Engl. J. Med. 372, 1333–1341 (2015).
pubmed: 25830423
pmcid: 4482354
Braunwald, E. The war against heart failure: the Lancet lecture. Lancet 385, 812–824 (2015).
pubmed: 25467564
Barzilai, N. et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290, 2030–2040 (2003).
pubmed: 14559957
Paolisso, G. et al. Glucose tolerance and insulin action in healthy centenarians. Am. J. Physiol. 270, E890–E894 (1996).
pubmed: 8967479
Evert, J., Lawler, E., Bogan, H. & Perls, T. Morbidity profiles of centenarians: survivors, delayers, and escapers. J. Gerontol. A: Biol. Sci. Med. Sci. 58, 232–237 (2003).
Rabuñal-Rey, R. et al. Electrocardiographic abnormalities in centenarians: impact on survival. BMC Geriatr. 12, 15 (2012).
pubmed: 22520618
pmcid: 3416736
Szewieczek, J. et al. ECG low QRS voltage and wide QRS complex predictive of centenarian 360-day mortality. Age (Dordr.) 38, 44 (2016).
Japan Statistical Yearbook 1900 (Statistic Bureau, Ministry of Internal Affairs and Communications, Tokyo, 1900).
Willcox, D. C. et al. Life at the extreme limit: phenotypic characteristics of supercentenarians in Okinawa. J. Gerontol. A Biol. Sci. Med. Sci. 63, 1201–1208 (2008).
pubmed: 19038835
Andersen, S. L., Sebastiani, P., Dworkis, D. A., Feldman, L. & Perls, T. T. Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span. J. Gerontol. A Biol. Sci. Med. Sci. 67, 395–405 (2012).
pubmed: 22219514
Arai, Y. et al. Physical independence and mortality at the extreme limit of life span: supercentenarians study in Japan. J. Gerontol. A Biol. Sci. Med. Sci. 69, 486–494 (2014).
pubmed: 24225329
Dong, X., Milholland, B. & Vijg, J. Evidence for a limit to human lifespan. Nature 538, 257–259 (2016).
pubmed: 27706136
Barbi, E., Lagona, F., Marsili, M., Vaupel, J. W. & Wachter, K. W. The plateau of human mortality: demography of longevity pioneers. Science 360, 1459–1461 (2018).
pubmed: 29954979
pmcid: 6457902
de Lemos, J. A., McGuire, D. K. & Drazner, M. H. B-type natriuretic peptide in cardiovascular disease. Lancet 362, 316–322 (2003).
pubmed: 12892964
Belonje, A. M. et al. Endogenous erythropoietin and outcome in heart failure. Circulation 121, 245–251 (2010).
pubmed: 20048213
George, J. et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92, 1420–1424 (2006).
pubmed: 16621874
pmcid: 1861042
Parenica, J. et al. Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients—multiple biomarkers prospective cohort study. Int. J. Cardiol. 211, 96–104 (2016).
pubmed: 26991556
Braunwald, E. Biomarkers in heart failure. N. Engl. J. Med. 358, 2148–2159 (2008).
pubmed: 18480207
Tabata, M. et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. Cell Metab. 10, 178–188 (2009).
pubmed: 19723494
Tian, Z. et al. ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism. Nat. Commun. 7, 13016 (2016).
pubmed: 27677409
pmcid: 5052800
Harjola, V. P. et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. J. Heart Fail. 19, 821–836 (2017).
pubmed: 28560717
pmcid: 5734941
Fliser, D. & Ritz, E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am. J. Kidney Dis. 37, 79–83 (2001).
pubmed: 11136171
Meng, F. et al. Assessment of the value of serum cholinesterase as a liver function test for cirrhotic patients. Biomed. Rep. 1, 265–268 (2013).
pubmed: 24648933
pmcid: 3917072
Sebastiani, P. et al. Age and sex distributions of age-related biomarker values in healthy older adults from the Long Life Family Study. J. Am. Geriatr. Soc. 64, e189–e194 (2016).
pubmed: 27783390
pmcid: 5118076
Corti, M. C., Guralnik, J. M., Salive, M. E. & Sorkin, J. D. Serum albumin level and physical disability as predictors of mortality in older persons. JAMA 272, 1036–1042 (1994).
pubmed: 8089886
Gondo, Y. et al. Functional status of centenarians in Tokyo, Japan: developing better phenotypes of exceptional longevity. J. Gerontol. A Biol. Sci. Med. Sci. 61, 305–310 (2006).
pubmed: 16567382
Takayama, M. et al. Morbidity of Tokyo-area centenarians and its relationship to functional status. J. Gerontol. A: Biol. Sci. Med. Sci. 62, 774–782 (2007).
Arai, Y. et al. Inflammation, but not telomere length, predicts successful ageing at extreme old age: a longitudinal study of semi-supercentenarians. EBioMedicine 2, 1549–1558 (2015).
pubmed: 26629551
pmcid: 4634197
Arai, Y. et al. The Tokyo oldest old survey on total health (TOOTH): a longitudinal cohort study of multidimensional components of health and well-being. BMC Geriatr. 10, 35 (2010).
pubmed: 20529368
pmcid: 2893189
Juul, K. et al. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation 109, 59–65 (2004).
pubmed: 14662715
Haibe-Kains, B., Desmedt, C., Sotiriou, C. & Bontempi, G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24, 2200–2208 (2008).
pubmed: 18635567
pmcid: 2553442
Levin, E. R., Gardner, D. G. & Samson, W. K. Natriuretic peptides. N. Engl. J. Med. 339, 321–328 (1998).
pubmed: 9682046
Hama, N. et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92, 1558–1564 (1995).
pubmed: 7664440
Fisher, C., Berry, C., Blue, L., Morton, J. J. & McMurray, J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89, 879–881 (2003).
pubmed: 12860863
pmcid: 1767758
Komajda, M. et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ. Heart Fail. 4, 27–35 (2011).
pubmed: 21068341
Kragelund, C., Grønning, B., Køber, L., Hildebrandt, P. & Steffensen, R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N. Engl. J. Med. 352, 666–675 (2005).
pubmed: 15716560
Patton, K. K. et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 120, 1768–1774 (2009).
pubmed: 19841297
pmcid: 4132053
Zethelius, B. et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med. 358, 2107–2116 (2008).
pubmed: 18480203
Vaes, B., de Ruijter, W., Degryse, J., Westendorp, R. G. & Gussekloo, J. Clinical relevance of a raised plasma N-terminal pro-brain natriuretic peptide level in a population-based cohort of nonagenarians. J. Am. Geriatr. Soc. 57, 823–829 (2009).
pubmed: 19470010
York, M. K. et al. B-type natriuretic peptide levels and mortality in patients with and without heart failure. J. Am. Coll. Cardiol. 71, 2079–2088 (2018).
pubmed: 29747827
pmcid: 5951190
Chow, S. L. et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 135, e1054–e1091 (2017).
pubmed: 28446515
Wastesson, J. W., Parker, M. G., Fastbom, J., Thorslund, M. & Johnell, K. Drug use in centenarians compared with nonagenarians and octogenarians in Sweden: a nationwide register-based study. Age. Ageing 41, 218–224 (2012).
pubmed: 22130561
Andersen-Ranberg, K., Schroll, M. & Jeune, B. Healthy centenarians do not exist, but autonomous centenarians do: a population-based study of morbidity among Danish centenarians. J. Am. Geriatr. Soc. 49, 900–908 (2001).
pubmed: 11527481
Evans, C. J. et al. Place and cause of death in centenarians: a population-based observational study in England, 2001 to 2010. PLoS Med. 11, e1001653 (2014).
pubmed: 24892645
pmcid: 4043499
Berzlanovich, A. M. et al. Do centenarians die healthy? An autopsy study. J. Gerontol. A: Biol. Sci. Med. Sci. 60, 862–865 (2005).
Motta, M. et al. Autopsy reports in extreme longevity. Arch. Gerontol. Geriatr. 50, 48–50 (2010).
pubmed: 19285737
Alfaras, I. et al. Pharmacological strategies to retard cardiovascular aging. Circ. Res. 118, 1626–1642 (2016).
pubmed: 27174954
pmcid: 4894351
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmark of ageing. Cell 153, 1194–1217 (2013).
pubmed: 3836174
pmcid: 3836174
Cesari, M. et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108, 2317–2322 (2003).
pubmed: 14568895
Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat. Rev. Cardiol. 15, 505–522 (2018).
pubmed: 30065258
pmcid: 6146930
Doi, Y. et al. Angiopoietin-like protein 2 and risk of type 2 diabetes in a general Japanese population: the Hisayama study. Diabetes Care 36, 98–100 (2013).
pubmed: 22966088
Hata, J. et al. Serum angiopoietin-like protein 2 is a novel risk factor for cardiovascular disease in the community: the Hisayama Study. Arterioscler. Thromb. Vasc. Biol. 36, 1686–1691 (2016).
pubmed: 27365403
Sullivan, D. H., Sun, S. & Walls, R. C. Protein-energy undernutrition among elderly hospitalized patients: a prospective study. JAMA 281, 2013–2019 (1999).
pubmed: 10359390
Kaysen, G. A. et al. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int. 61, 2240–2249 (2002).
pubmed: 12028466
Fuhrman, M. P., Charney, P. & Mueller, C. M. Hepatic proteins and nutrition assessment. J. Am. Diet. Assoc. 104, 1258–1264 (2004).
pubmed: 15281044
Ancion, A. et al. Serum albumin level and long-term outcome in acute heart failure. Acta Cardiol. 74, 465–471 (2019).
pubmed: 30650026
von Berenberg, P. et al. Chronic conditions and use of health care service among German centenarians. Age. Ageing 46, 939–945 (2017).
Benetos, A., Petrovic, M. & Strandberg, T. Hypertension management in older and frail older patients. Circ. Res. 124, 1045–1060 (2019).
pubmed: 30920928
Streit, S., Poortvliet, R. K. E. & Gussekloo, J. Lower blood pressure during antihypertensive treatment is associated with higher all-cause mortality and accelerated cognitive decline in the oldest-old. Data from the Leiden 85-plus Study. Age. Ageing 47, 545–550 (2018).
pubmed: 29741555
Pfister, R. et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 8, e1001112 (2011).
pubmed: 22039354
pmcid: 3201934
Adachi, T. et al. Quantitative and qualitative changes of extracellular-superoxide dismutase in patients with various diseases. Clin. Chim. Acta 229, 123–131 (1994).
pubmed: 7988042
Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982–992 (2009).
pubmed: 19339088
Di Angelantonio, E. et al. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ 341, c4986 (2010).
pubmed: 20884698
pmcid: 2948649
Pearson, T. A. et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499–511 (2003).
pubmed: 12551878
Tibshirani, R. The lasso method for variable selection in the Cox model. Stat. Med. 16, 385–395 (1997).
pubmed: 9044528
Pavlou, M. et al. How to develop a more accurate risk prediction model when there are few events. BMJ 351, h3868 (2015).
pubmed: 4531311
pmcid: 4531311
Smith, G. C., Seaman, S. R., Wood, A. M., Royston, P. & White, I. R. Correcting for optimistic prediction in small data sets. Am. J. Epidemiol. 180, 318–324 (2014).
pubmed: 24966219
pmcid: 4108045
Harrell, F. E. Jr, Lee, K. L. & Mark, D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361–387 (1996).
pubmed: 8668867
Ridker, P. M. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ. Res. 118, 145–156 (2016).
pubmed: 26837745
pmcid: 4793711